942277-74-9Relevant academic research and scientific papers
Performance of chiral tetracarbonylmolybdenum pyrindanyl amine complexes in catalytic olefin epoxidation
Neves, Patrícia,Nogueira, Lucie S.,Valente, Anabela A.,Pillinger, Martyn,Gon?alves, Isabel S.,Sampaio-Dias, Ivo E.,Sousa, Carlos A.D.,Rizzo-Aguiar, Fabio,Rodríguez-Borges, José E.
, p. 29 - 36 (2018)
Tetracarbonylmolybdenum(0) complexes of the type cis-[Mo(CO)4(L)] containing chiral 7-(1-pyrindanyl) amine ligands were prepared and found to be effective precatalysts for the epoxidation of achiral (cis-cyclooctene) and prochiral (DL-limonene and trans-β-methylstyrene) olefins at 55 °C. Epoxides were the only products formed from cis-cyclooctene (100% yield) and trans-β-methylstyrene (100% selectivity at 82–85% conversion), and the main products formed from DL-limonene (80–82% 1,2-epoxide selectivity at 85% conversion). Characterization of recovered catalysts revealed that the precatalysts were transformed in situ to stable polyoxomolybdate salts containing the β-octamolybdate anion [β-Mo8O26]4?, which was responsible for the catalytic reaction.
CANNABINOID ACTIVE PHARMACEUTICAL INGREDIENT FOR IMPROVED DOSAGE FORMS
-
Page/Page column 86, (2010/11/25)
Pharmaceutical compositions comprising the cannabinoid active pharmaceutical ingredient, crystalline trans-(±)-Δ9-tetrahydrocannabinol, and formulations thereof are disclosed. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of crystalline trans-(±)-Δ9-tetrahydrocannabinol. In specific embodiments, the crystalline trans-(±)-Δ9-tetrahydrocannabinol administered according to the methods for treating or preventing a condition such as pain can have a purity of at least about 98% based on the total weight of cannabinoids.
